• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Endocare

Endocare

Endocan Corp ENDO

Last Price$0.03Day Change (%)-0.34%
Open Price$0.02Day Change ($)0.00
Day Range0.02–0.0352-Week Range0.02–0.18

As of Thu 10/23/2014 11:33 AM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. AUXILIUM PHARMACEUTICALS INC. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Auxilium Pharmaceuticals Inc. Over the Proposed Sale of the Company to Endo International PLC -AUXL

    AUXILIUM PHARMACEUTICALS INC. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Auxilium Pharmaceuticals Inc. Over the Proposed Sale of the Company to Endo International PLC -AUXL

  2. AUXILIUM PHARMACEUTICALS INC. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Auxilium Pharmaceuticals Inc. (AUXL) over the Proposed Sale of the Company to Endo International PLC ...

    AUXILIUM PHARMACEUTICALS INC. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Auxilium Pharmaceuticals Inc. (AUXL) over the Proposed Sale of the Company to Endo International PLC (ENDP)

  3. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Investigates the Board of Directors of Auxilium Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company to Endo International

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Investigates the Board of Directors of Auxilium Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company to Endo International

  4. Endo To Acquire Auxilium Pharmaceuticals In A Cash And Stock Transaction For Approximately $2.6 Billion

    Endo To Acquire Auxilium Pharmaceuticals In A Cash And Stock Transaction For Approximately $2.6 Billion

  5. Endo To Acquire Auxilium Pharmaceuticals In A Cash And Stock Transaction For Approximately $2.6 Billion

    Endo To Acquire Auxilium Pharmaceuticals In A Cash And Stock Transaction For Approximately $2.6 Billion

  6. Endo to buy Auxilium in $2.6 billion deal

    Endo to buy Auxilium in $2.6 billion deal

  7. The Market: Exaggerated Woes

    Endo Pharmaceuticals ENDP announced July 11 that it no longer expects to file a new drug application for its ketoprofen pain-relief patch by the first half of 2008 because of lackluster Phase III trial results. The drug candidate failed to show statistically significant results for pain relief in ...

  8. SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Auxilium Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

    SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Auxilium Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

  9. Endo Reaches Master Settlement Agreements to Resolve Substantially All Remaining AMS Mesh Litigation Claims

    Endo Reaches Master Settlement Agreements to Resolve Substantially All Remaining AMS Mesh Litigation Claims

  10. Research and Markets: Global Laparoscopic Devices Market 2014-2018: Key Vendors Are Cardinal Health, Covidien, Ethicon Endo -Surgery, KARL STORZ, Olympus Europa & Stryker

    Research and Markets: Global Laparoscopic Devices Market 2014-2018: Key Vendors Are Cardinal Health, Covidien, Ethicon Endo -Surgery, KARL STORZ, Olympus Europa & Stryker

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.